The burgeoning research on osimertinib resistance in NSCLC has delineated 2 overarching categories of resistance mechanisms: EGFR-dependent (targeted) and EGFR-independent (off-target) mechanisms (12, 59–62). This evidence concerns the gene EGFR and non-small cell lung carcinoma.